Heavy chain and light chain variable regions of anti-human BAFF monoclonal antibody

Abstract

The invention discloses heavy chain and light chain variable regions of an anti-human BAFF monoclonal antibody. The anti-human BAFF monoclonal antibody is FMMU-BAFF-4, wherein the gene sequences of the monoclonal antibody variable regions are shown as SEQ ID NO.3 and SEQ ID NO.4; and the amino acid sequences of the monoclonal antibody variable regions are shown as SEQ ID NO.1 and SEQ ID NO.2. In the variable regions, a mouse anti-human BAFF monoclonal antibody is prepared by using a recombined human BAFF immunological BALB/c mouse; the mouse anti-human BAFF monoclonal antibody is cloned and screened to obtain a hybridoma cell line which can secrete specific human BAFF monoclonal antibody FMMU-BAFF-NO.4; the genes of the monoclonal antibody light chain and heavy chain variable regions are cloned to obtain the gene sequences and the amino acid sequences of the monoclonal antibody light and heavy chain variable regions, and CDR sequences of the variable regions; and the uniqueness of the amino acid sequences and the gene sequences is determined.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to a monoclonal antibody, in particular to a heavy chain and light chain variable region of an anti-human BAFF monoclonal antibody, including its amino acid sequence and its nucleotide sequence. Background technique [0002] Autoimmune diseases refer to the diseases caused by the body's immune response to self-antigens, resulting in damage to its own tissues, and are diseases that seriously endanger human health. Common autoimmune diseases include systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and rheumatoid arthritis (RA). The treatment methods for autoimmune diseases are still in the research and exploration stage, mainly relying on drugs such as immunosuppressants, physical therapy and surgical treatment, but the side effects are relatively large and cannot be cured. Therefore, targeted antibody drug therapy combined with genetic engineering and protein engineerin...

AI Technical Summary

Problems solved by technology

[0004] At present, the preparations that block the biological activity of BAFF mainly include anti-BAFF antibodies and BAFF soluble receptors, among which anti-BAFF antibodies include lymphostat-B, EGFP/scFv F8, anti-BAFFscFv, anti-BAFF scFv-Fc etc., b...

Images